Polycythemia vera

Common Name(s)

Polycythemia vera

Polycythemia vera (PV) is a condition characterized by an increased number of red blood cells in the bloodstream. Affected people may also have excess white blood cells and platelets. These extra cells cause the blood to be thicker than normal, increasing the risk for blood clots that can block blood flow in arteries and veins. People with PV have an increased risk of deep vein thrombosis which can cause a pulmonary embolism, heart attack, and stroke. Most cases of PV are not inherited and are acquired during a person's lifetime. In rare cases, the risk for PV runs in families and may be inherited in an autosomal dominant manner. The condition has been associated with mutations in the JAK2 and TET2 genes.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Polycythemia vera" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Polycythemia vera" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Polycythemia vera" returned 424 free, full-text research articles on human participants. First 3 results:

An oncolytic parasite to treat polycythemia vera.
 

Author(s): Syeda Taliya Rizvi, Omar Bagasra

Journal:

 

Last Updated: 9 Nov 2015

Go To URL

Last Updated: 3 Oct 2015

Go To URL
Polycythemia Vera Diagnosed after Esophageal Variceal Rupture.
 

Author(s): Yoshiyasu Kono, Akinobu Takaki, Hideo Gobara, Ken-Ichi Matsuoka, Masato Nishino, Hiroyuki Okada, Kazuhide Yamamoto

Journal: Intern. Med.. 2015 ;54(18):2395-9.

 

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that leads to hyperviscosity and the risk of thrombosis. We encountered the case of a young male Filipino patient diagnosed with PV after the rupture of esophageal varices. The complete blood cell count showed a slight ...

Last Updated: 15 Sep 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Polycythemia vera" returned 29 free, full-text review articles on human participants. First 3 results:

Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
 

Author(s): Brady L Stein, Stephen T Oh, Dmitriy Berenzon, Gabriela S Hobbs, Marina Kremyanskaya, Raajit K Rampal, Camille N Abboud, Kenneth Adler, Mark L Heaney, Elias J Jabbour, Rami S Komrokji, Alison R Moliterno, Ellen K Ritchie, Lawrence Rice, John Mascarenhas, Ronald Hoffman

Journal: J. Clin. Oncol.. 2015 Nov;33(33):3953-60.

 

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that is associated with a substantial symptom burden, thrombohemorrhagic complications, and impaired survival. A decade after the seminal discovery of an activating mutation in the tyrosine kinase JAK2 in nearly all patients ...

Last Updated: 21 Nov 2015

Go To URL
New Therapeutic Approaches in Polycythemia Vera.
 

Author(s): Lorenzo Falchi, Kate J Newberry, Srdan Verstovsek

Journal: Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl():S27-33.

 

Polycythemia vera (PV) is 1 of the 3 Philadelphia-negative myeloproliferative neoplasms. Clinically, PV is an indolent disease, but its course can be complicated by arterial and venous vascular incidents, evolution to myelofibrosis, or leukemic transformation. Treatment of PV is therefore ...

Last Updated: 22 Aug 2015

Go To URL
Ruxolitinib for the treatment of patients with polycythemia vera.
 

Author(s): Jean-Jacques Kiladjian, Elliott F Winton, Moshe Talpaz, Srdan Verstovsek

Journal: Expert Rev Hematol. 2015 Aug;8(4):391-401.

 

Polycythemia vera (PV) is a hematopoietic proliferative disorder associated with Janus-associated kinase/signal transducer and activator of transcription pathway dysregulation resulting in erythrocytosis and, possibly, leukocytosis and thrombocytosis. Patients diagnosed with PV experience ...

Last Updated: 7 Jul 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
 

Status: Recruiting

Condition Summary: Polycythemia Vera; Essential Thrombocythemia; Myelofibrosis

 

Last Updated: 17 Mar 2016

Go to URL

Last Updated: 28 Jul 2016

Go to URL
Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features
 

Status: Not yet recruiting

Condition Summary: Polycythemia Vera

 

Last Updated: 21 Jun 2016

Go to URL